Future Directions in the Treatment of Recurrent or Metastatic Cervical Cancer

Author(s):

Bradley Monk, MD,Dana M. Chase, MD, FACOG

The panel closes their discussion by highlighting challenges in the treatment of cervical cancer, emphasizing the need for more focus on clinical trials and therapies, as well as addressing disparities in cancer care, particularly for patients of color.

EP: 1.Diagnosing and Staging Patients With Endometrial Cancer

EP: 2.Updated NCCN Guidelines for the Treatment of Advanced or Recurrent Endometrial Cancer

EP: 3.Shared Decision-Making in Advanced or Recurrent Endometrial Cancer

EP: 4.The Role of dMMR in the Progression of Endometrial Cancer

EP: 5.Dostarlimab Plus Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Cancer: Data from the RUBY Trial

EP: 6.The NRG-GY018 Trial: Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer

EP: 7.Emerging Data on Combination Therapies in Advanced or Recurrent Endometrial Cancer

EP: 8.Advances in Anti-HER2 ADCs in Patients With Advanced or Recurrent Endometrial Cancer

EP: 9.Recent Data on Anti-TROP2 ADCs for Patients With Advanced or Recurrent Endometrial Cancer

EP: 10.Future Directions in the Treatment of Advanced or Recurrent Endometrial Cancer

EP: 11.Staging and Biomarker Testing For Patients With Cervical Cancer

EP: 12.Recent Updates in NCCN Guidelines for the Treatment of Recurrent or Metastatic Cervical Cancer

EP: 13.Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer

EP: 14.Ocular Toxicity Management Strategies for Patients With Cervical Cancer Receiving ADCs

EP: 15.Clinical Trials Evaluating Tisotumab Vedotin in Patients with Recurrent or Metastatic Cervical Cancer

EP: 16.Emerging Data on Anti-HER2 ADCs in Patients With Cervical Cancer

Now Viewing